Clinical Trials Logo

Filter by:
NCT ID: NCT04925817 Completed - Breast Carcinoma Clinical Trials

3D Ultrasound Microvessel Imaging for Breast Masses

Start date: August 19, 2021
Phase: Early Phase 1
Study type: Interventional

This early phase I trial studies how well 3D ultrasound microvessel imaging works for the diagnosis of breast mass. The 3D ultrasound microvessel imaging technology demonstrates significantly increased vessel detection sensitivity over conventional doppler methods without the need of using contrast agents. This study may improve cancer diagnosis and reduce unnecessary biopsy on benign tumors.

NCT ID: NCT04925765 Completed - Pregnancy Related Clinical Trials

Virtual Reality Biofeedback for Postpartum Anxiety and Depression

VITALISE
Start date: September 1, 2021
Phase: N/A
Study type: Interventional

The purpose of this study is to test patient feasibility and acceptability of virtual reality biofeedback program in postpartum women for anxiety and depression outcomes.

NCT ID: NCT04925713 Completed - Clinical trials for Basal Cell Carcinoma

IFx-Hu2.0 for the Treatment of Patients With Skin Cancer

Start date: June 10, 2021
Phase: Phase 1
Study type: Interventional

One hundred patients will receive IFx-Hu2.0 on an outpatient basis at a single time point in a single lesion. These patients will be assessed for any immediate adverse reactions and at Week 4 (Day 28+/-5 days) for any delayed adverse events..

NCT ID: NCT04925700 Completed - Oral Cancer Clinical Trials

The Oral Microbiome in OSCC

Start date: April 20, 2022
Phase: N/A
Study type: Interventional

Previous work by a number of scientific teams has revealed that the types of bacteria that colonize the mouth differ between health and pre-cancerous or cancerous oral lesions. The purpose of this study is to investigate the extent of these changes and to correlate the changes with alterations in the activities of the host's own oral tissues. In doing so, we believe we can gain a better understanding of how particular bacterial species, or consortia of species, can result in an individual having an increased risk of the most common type of oral cancer -- oral squamous cell carcinoma. This knowledge may also lead to the identification of salivary biomarkers that can be used for clinical evaluation or screening. In addition, we seek to determine the extent to which a probiotic regimen can help prevent or rectify the disease-related changes in the types of bacterial colonizing the mouth. The microbiome in health, pre-cancerous lesions, and cancerous lesions will be determined from remnant microbial DNA in banked tissue samples. The effects of probiotics on the oral microbiome will be determined from DNA collected from swabs of oral tissue at baseline and then after 3 to 6 months of probiotic usage.

NCT ID: NCT04925687 Completed - Clinical trials for Retinitis Pigmentosa

Phase 1 Study of Intravitreal Autologous CD34+ Stem Cell Therapy for Retinitis Pigmentosa

BMSCRP1
Start date: June 1, 2021
Phase: Phase 1
Study type: Interventional

In this Phase 1 open-labeled prospective study, one eye of each participant with vision loss from retinitis pigmentosa will be administered intravitreal injection of autologous CD34+ stem cells harvested from bone marrow. Each participant will be examined serially for 6 months after study injection to determine safety and feasibility of this intervention.

NCT ID: NCT04925622 Completed - Parkinson Disease Clinical Trials

Complex Eye Movements in Parkinson's Disease and Related Movement Disorders

Start date: January 4, 2021
Phase:
Study type: Observational [Patient Registry]

Diagnosing Parkinson's disease (PD) depends on the clinical history of the patient and the patient's response to specific treatments such as levodopa. Unfortunately, a definitive diagnosis of PD is still limited to post-mortem evaluation of brain tissues. Furthermore, diagnosis of idiopathic PD is even more challenging because symptoms of PD overlap with symptoms of other conditions such as essential tremor (ET) or Parkinsonian syndromes (PSs) such as progressive supranuclear palsy (PSP), multiple system atrophy (MSA), corticobasal degeneration (CBD), or vascular Parkinsonism (VaP). Based on the principle that PD and PSs affect brain areas involved in eye movement control, this trial will utilize a platform that records complex eye movements and use a proprietary algorithm to characterize PSs. Preliminary data demonstrate that by monitoring oculomotor alterations, the process can assign PD-specific oculomotor patterns, which have the potential to serve as a diagnostic tool for PD. This study will evaluate capabilities of the process and its ability to differentiate PD from other PSs with statistical significance. The specific aims of this proposal are: To optimize the detection and analysis algorithms, and then to evaluate the process against neurological diagnoses of PD patients in a clinical study.

NCT ID: NCT04925570 Completed - Clinical trials for Substance Use Disorders

The Anchor Study: Digitally Delivered Intervention for Reducing Problematic Substance Use

Start date: November 14, 2022
Phase: Phase 2
Study type: Interventional

This study aims to validate W-SUDs as a digitally-delivered substance use disorder program through a fully-powered randomized control trial that will test the comparative efficacy of the mobile-app based substance use disorder program (W-SUDs) to reduce substance use relative to a psychoeducation control condition, which has no cognitive behavioral therapy and the content is not delivered through a conversational user interface.

NCT ID: NCT04925557 Completed - Clinical trials for Secondary-progressive Multiple Sclerosis

Study to Assess the Efficacy of Mayzent on Microglia in Secondary Progressive Multiple Sclerosis

Start date: November 13, 2021
Phase: Phase 2/Phase 3
Study type: Interventional

To assess the efficacy of Mayzent on microglia pathology in patients with active SPMS, as compared to the active control group of MS patients treated with the Ocrevus, as measured by changes in microglial activation in the lesional and non-lesional NAWM and NAGM and in the peri-plaque area of chronic lesions in the brain.

NCT ID: NCT04925271 Completed - Fistula Clinical Trials

Closure of Mucosal and Submucosal Defects in the Gastrointestinal Tract Using the Novel X-Tack Endoscopic Suturing Device

Start date: July 1, 2021
Phase: N/A
Study type: Interventional

After removing large polyps from the gastrointestinal tract, gastroenterologists close the new defect with devices to prevent complications like bleeding or the development of a leak. Commonly, this is done with a device called Overstitch, which allows the gastroenterologist to stitch the defect with an endoscope. A new device called X-tack has been developed to simplify endoscopic stitching. In this study, the new X-tack device will be compared to Overstitch when closing defects in the gastrointestinal tract. The two devices will be compared to see how long it takes to close a defect, as well as if there are any differences in complications like bleeding or infection.

NCT ID: NCT04925245 Completed - Echocardiography Clinical Trials

Clinical Reminder to Improve Appropriateness of Echocardiography

Start date: September 30, 2019
Phase: N/A
Study type: Interventional

This study will test a clinical reminder to show recent echocardiograms when a new echocardiogram is ordered. The goal is to avoid unnecessary comprehensive echocardiography.